Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (Nasdaq: MNKD) generates frequent news across product, clinical, regulatory, and corporate fronts as it advances therapies for cardiometabolic and orphan lung diseases. News coverage for MNKD often centers on its commercial products Afrezza, FUROSCIX, V-Go, and Tyvaso DPI–related collaborations, as well as updates on its inhaled and subcutaneous pipeline.
Investors and healthcare observers following MNKD news can expect announcements on U.S. Food and Drug Administration (FDA) milestones, including supplemental Biologics License Applications and supplemental New Drug Applications. Recent examples include FDA acceptance for review of an sBLA for Afrezza in children and adolescents with type 1 or type 2 diabetes, and acceptance of an sNDA for the FUROSCIX ReadyFlow Autoinjector for edema in adults with chronic heart failure or chronic kidney disease.
MannKind’s news flow also covers clinical trial progress and portfolio decisions in orphan lung diseases. The company has reported on initiation of nintedanib DPI (MNKD-201) studies for idiopathic pulmonary fibrosis, as well as the discontinuation of the Phase 3 ICoN-1 trial of nebulized clofazimine (MNKD-101) for refractory nontuberculous mycobacterial lung disease following a futility analysis. Updates on pre-clinical programs such as bumetanide DPI and MNKD-102 are also featured in its communications.
Corporate and financial news items include quarterly earnings results, revenue breakdowns across royalties, collaborations, and product sales, and strategic transactions. A notable example is MannKind’s acquisition of scPharmaceuticals, which brought FUROSCIX fully into its portfolio and expanded its presence in cardiometabolic care. The company also issues releases about investor conference presentations and community initiatives, such as the Centennial Al Mann Scholarship for students living with diabetes.
This news page aggregates these developments so readers can review regulatory decisions, trial outcomes, business combinations, and financial updates related to MannKind in one place.
MannKind Corporation (Nasdaq: MNKD), a developer of inhaled therapeutic products for endocrine and orphan lung diseases, has appointed Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer, effective September 29, 2025.
Dr. Ahuja brings over 20 years of biopharmaceutical leadership experience, most recently serving as Development and Launch Leader at Kardigan Bio. His extensive background includes senior roles at Idorsia Pharmaceuticals, Allergan, Takeda, Pfizer, and Novartis. Dr. Ahuja holds an MD from Washington University and an MBA from Harvard Business School, and practiced medicine at Boston Children's Hospital for over a decade.
MannKind Corporation (Nasdaq: MNKD), a developer of inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in four upcoming investor conferences in September 2025.
CEO Michael Castagna and CFO Chris Prentiss will present at the Wells Fargo Health Care Conference (Sept. 3), Cantor Global Healthcare Conference (Sept. 4), H.C. Wainwright Global Investment Conference (Sept. 9), and Morgan Stanley Global Healthcare Conference (Sept. 9). Live webcasts will be available on MannKind's investor relations website, with recordings accessible for 90 days post-event.
MannKind Corporation (NASDAQ: MNKD) has expanded its collaboration with United Therapeutics (NASDAQ: UTHR) to develop a second dry powder inhalation therapy. This follows their successful partnership that resulted in Tyvaso DPI, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.
Under the expanded agreement, MannKind will utilize its Technosphere® platform to formulate a new investigational molecule, while United Therapeutics will handle preclinical and clinical development. The deal includes an upfront payment of $5 million to MannKind, potential development milestones up to $35 million, and 10% royalties on net sales of any resulting product.
MannKind Corporation (Nasdaq: MNKD) has announced the acquisition of scPharmaceuticals in a deal valued up to $360 million. The transaction includes an upfront payment of $5.35 per share plus a CVR worth up to $1.00 per share tied to regulatory and sales milestones.
The acquisition brings FUROSCIX, an FDA-approved treatment for fluid overload in chronic heart failure and chronic kidney disease patients, with a $10+ billion U.S. market opportunity. scPharmaceuticals reported strong H1 2025 performance with net sales of $27.8 million, up 96% year-over-year. The combined company projects an annualized revenue run rate of over $370 million based on Q2 2025 results.
The deal is expected to close in Q4 2025, with Blackstone providing $175 million in additional funding. A FUROSCIX ReadyFlow Autoinjector sNDA submission is planned for Q3 2025, potentially reducing treatment time from five hours to under 10 seconds.
MannKind Corporation (Nasdaq: MNKD) has secured a strategic financing agreement worth up to $500 million with Blackstone. The deal includes a $75 million initial term loan at closing, a $125 million delayed draw term loan available for 24 months, and an additional $300 million uncommitted DDTL.
The non-dilutive financing, maturing in August 2030, bears interest at SOFR plus 4.75%. The funds will support MannKind's growth initiatives, including the commercial team expansion for Afrezza's potential pediatric indication, pipeline advancement, and business development opportunities.
MannKind Corporation (Nasdaq: MNKD) reported strong Q2 2025 financial results with total revenues of $76.5 million, up 6% year-over-year. The company achieved net income of $0.7 million in Q2 2025, compared to a net loss of $2.0 million in Q2 2024.
Key highlights include the submission of an sBLA for Afrezza in pediatric patients, with a review decision expected in early Q4 2025. The company's pipeline is advancing with the ICoN-1 trial for inhaled clofazimine (MNKD-101) enrollment ahead of schedule, and plans to initiate a Phase 2 trial for nintedanib DPI (MNKD-201) in IPF by year-end 2025.
Revenue growth was driven by a 22% increase in royalties from Tyvaso DPI sales and a 13% increase in Afrezza revenue to $18.3 million. The company maintained a strong financial position with $201.2 million in cash and investments as of June 30, 2025.
MannKind Corporation (NASDAQ: MNKD) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, before the market opens. The company will host a conference call and webcast at 9:00 a.m. Eastern Time to discuss the results and provide business updates.
The presentation will be accessible through MannKind's investor relations website, with a replay available for approximately 90 days after the event.
MannKind Corporation (MNKD) is partnering with NTT INDYCAR SERIES driver Conor Daly for a special event during the Chevrolet Detroit Grand Prix week. The event, scheduled for May 29, 2025, at Full-Throttle Adrenaline Park in Novi, MI, will feature Daly sharing his experience living with Type 1 diabetes and racing go-karts with local youth.
Daly, diagnosed with T1D at age 14, is the only known U.S. professional racing driver competing full-time with the condition. He will drive the No. 76 "Tired of Pricks?" Chevrolet for Juncos Hollinger Racing at the Detroit Grand Prix. His notable achievements include a career-best 6th place finish at the 2022 Indy 500, leading the most laps at the 2021 Indy 500, and becoming the first driver to compete in both NASCAR and IndyCar on consecutive Texas weekends in 2023.
MannKind Corporation (MNKD), a company specializing in inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in two upcoming investor conferences. CEO Michael Castagna and CFO Chris Prentiss will present at:
- RBC Capital Markets 2025 Global Annual Healthcare Conference on Tuesday, May 20 at 8:00 a.m. ET
- Jefferies Global Healthcare Conference on Thursday, June 5 at 2:35 p.m. ET
Both conferences will be held in New York City. Live audio webcasts will be available on MannKind's investor relations website, with recordings accessible for approximately 90 days after the events.
FAQ
What is the current stock price of Mannkind (MNKD)?
What is the market cap of Mannkind (MNKD)?
